Determinants of thyrotoxic cardiomyopathy recovery.

The purpose was to evaluate the effect of the disease duration prior to treatment, thyroid hormones level, or both on the reversibility of dilated cardiomyopathy. Between January 2006 and December 2010, a longitudinal study with a 6 months follow-up was carried on. One hundred and seventy patients with hyperthyroidism were referred to the cardiologist, and 127 had a 6 months followup after antithyroid treatment and were evaluated by echocardiography. Dilated cardiomyopathy reversibility criteria were established according to echocardiographic parameters. Complete reversibility existed when all parameters were met, partial reversibility when LVEF was ≥55% plus two or three other parameters, and no reversibility when LVEF was ≤55% regardless of other parameters. The results showed that echocardiography parameters related to the regression of myocardial mass were associated with a disease duration shorter than 10.38 months. This was the main predictive variable for reversal of dilated cardiomyopathy, followed by ß -blocker treatment, and the last predictive variable was the serum level of free triiodothyronine. This study showed that the effect on the myocardium related to thyrotoxicosis was associated with the disease duration before treatment.

[Prevalence of syncope in a sample of Mexican women residents in Mexico City]. / Prevalencia de síncope en una muestra de mujeres mexicanas residentes de la ciudad de México.

OBJECTIVE: To identify the frequency of syncope in a sample of women regular residents of Mexico City. METHODS: Two hundred and twenty one women between 18 and 88 years old with voluntary participation were included in the study. Trained interviewers through a structured questionnaire obtained syncope information. Prevalence of syncope was obtained, and it's relation with: age, time since the last syncope and frequency of syncope in their live span was registered. RESULTS: Thirty eight percent informed they had suffered syncope, of them 50% had only one syncopal episode during their lives. The others had two or more episodes. Most women had their last syncope between 19 and 50 years of age. CONCLUSIONS: The frequency of syncope was a little higher than previous studies. This is a first approximation, which must be corroborated with larger studies with well population variability representation.

[Vasovagal syncope: from genetic to bedside]. / Avances en síncope vasovagal: de la genética a la clínica.

Recent studies suggest vasovagal syncope has a significant heritable component indicating that, at least some forms of vasovagal syncope may have a genetic cause. The beta1-adrenergic receptor is a key cell surface signaling protein expressed in the heart and major determinant of cardiac function. The role of genetics in the phenotypic manifestations of vasovagal syncope is unclear. Here, we report the characteristics of several families with several affected members with vasovagal syncope, as well as the results of several genetic studies exploring the prevalence of polymorphisms in the beta1 adrenergic receptors which may be associated with vasovagal syncope.

[Electrophysiologic study and ablation therapy in idiopathic paroxystic atrial fibrillation]. / Estudio electrofisiológico y ablación de actividad eléctrica anormal en venas pulmonares de pacientes con fibrilación auricular paroxística idiopática.

OBJECTIVE: To analyze the results of radiofrequency catheter ablation (RFCA) of the pulmonary veins (PV) in patients with paroxysmal atrial fibrillation (PAF). MATERIAL AND METHODS: We describe 4 patients (38 +/- 12 years, interval 8-52; 11 men) with symptomatic PAF, refractory to antiarrhythmic drugs. Special mapping catheters were used and ablation was performed at the ostium/antrum of those veins with abnormal electrical activity (AEA). RESULTS: AEA in one or more PV was identified in 13 patients (86%); in one patient AEA was also found in the superior vena cava (6.6%). One procedure was complicated by unstable ventricular tachycardia and was notfinished. Success was accomplished in 10, in 5 after the first ablation, in 4 after the second, and in one after a third procedure. One patient had pericarditis with a small pericardial effusion that did not require intervention. CONCLUSIONS: RFCA is a useful and relatively safe procedure for the treatment of PAF and the only one with curative potential. The long-term rate of success (with or without antiarrhythmics) in this series was 71%. These results justify catheter ablation in selected patients with symptomatic PAF unresponsive to medical treatment.

Estudio electrofisiológico y ablación de actividad eléctrica anormal en venas pulmonares de pacientes con fibrilación auricular paroxística idiopática / Electrophysiologic study and ablation therapy in idiopathic paroxystic atrial fibrillation

Objetivo: Informar la ablación en las venas pulmonares (VPs) en pacientes con fibrilación auricular paroxística (FAP). Material y métodos: Catorce pacientes (38±12 años [intervalo 8-52, 11 hombres, 3 mujeres) con FAP idiopática, sintomática y refractarios a antiarrítmicos y con estudio electrofisiológico. En 13 se encontró actividad eléctrica anormal (AEA) en VPs mediante catéteres especiales de cartografía y se realizó ablación. Resultados: Se identificó AEA en VP’s (13 pacientes, 86%) y en vena cava superior (un paciente, 6.6%). Un procedimiento fue suspendido por taquicardia ventricular. La ablación fue exitosa en 7 de los 12 pacientes restantes. Los cinco pacientes con ablación inicial fallida fueron llevados a un segundo procedimiento que fue exitoso en dos. En un paciente fue necesario un tercer procedimiento que resultó exitoso. Una paciente tuvo pericarditis con derrame ligero que no requirió drenaje. Conclusión: La ablación de FAP es un procedimiento seguro con una tasa de éxito combinada (con y sin antiarrítmicos) en esta población y a largo plazo, del 71%.

OBJECTIVE: To analyze the results of radiofrequency catheter ablation (RFCA) of the pulmonary veins (PV) in patients with paroxysmal atrial fibrillation (PAF). MATERIAL AND METHODS: We describe 4 patients (38 +/- 12 years, interval 8-52; 11 men) with symptomatic PAF, refractory to antiarrhythmic drugs. Special mapping catheters were used and ablation was performed at the ostium/antrum of those veins with abnormal electrical activity (AEA). RESULTS: AEA in one or more PV was identified in 13 patients (86%); in one patient AEA was also found in the superior vena cava (6.6%). One procedure was complicated by unstable ventricular tachycardia and was notfinished. Success was accomplished in 10, in 5 after the first ablation, in 4 after the second, and in one after a third procedure. One patient had pericarditis with a small pericardial effusion that did not require intervention. CONCLUSIONS: RFCA is a useful and relatively safe procedure for the treatment of PAF and the only one with curative potential. The long-term rate of success (with or without antiarrhythmics) in this series was 71%. These results justify catheter ablation in selected patients with symptomatic PAF unresponsive to medical treatment.